Promising drug trodelvy tested as first defense against aggressive breast cancer

NCT ID NCT07299409

Not yet recruiting Disease control Sponsor: Nathalie Levasseur Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing the drug sacituzumab govitecan (Trodelvy) as a first treatment for people with advanced triple-negative breast cancer who haven't had prior therapy for advanced disease. Researchers want to see if the drug can shrink tumors or slow the cancer's growth. The study will also compare how well the drug works in different genetic subtypes of the cancer. About 24 adults will take part, receiving the drug intravenously on days 1 and 8 of each 21-day cycle.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sacituzumab govitecan (Trodelvy)
What this could lead to: If successful, this could provide a new first-line treatment option for advanced triple-negative breast cancer, potentially slowing disease progression.
What could go wrong: This is a small, early-phase (Phase 2) study with only 24 participants, so results may not apply to all patients. The drug may cause side effects like nausea, diarrhea, or low blood cell counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED TRIPLE-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED TRIPLE-NEGATIVE BREAST CANCER BREAST CANCER BREAST CANCER, METASTATIC

Contacts and locations

Locations

BC Cancer - Vancouver Center

Vancouver, British Columbia, V5Z 4E6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.